DataMEDS AI, Inc. (NASDAQ: MEDS, "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx and blockchain-enabled smart contracts platform PharmacyChain to provide integrated solutions for the generation, rationalization, intervention, transaction, and monetization of health data, has officially completed its stock trading symbol change to 'MEDS.' The Company began trading under the new symbol on the NASDAQ Capital Market at the start of trading on Wednesday, July 22, 2026.

The symbol change finalizes the corporate rebranding from the Company's prior name, Wellgistics Health, Inc. (NASDAQ: WGRX). For public companies, a ticker change is a market-facing step that can make a completed rebrand more visible to investors, customers, and partners, while the underlying business milestones remain tied to execution of announced transactions and regulatory filings. DataMEDS stated that it is focused on completing its previously disclosed series of acquisition and licensing transactions.

Gerald Commissiong, Interim Co-CEO of DataMEDS AI, Inc., said: "Trading under the new symbol 'MEDS' is expected to help capture the attention and focus of the Health IT-focused investment community by immediately aligning the Company's mission of continually acquiring and analyzing data with the desired outcome of making the best treatment decisions around when to initiate prescription drug therapy, when to adjust dosing and/or when to discontinue treatment in the minds of investors."

Commissiong added: "For patients and healthy users, DataMEDS intends to go far beyond existing health IT platforms by providing our unique adjunct natural products to help improve health outcomes of patients on prescription GLP-1 treatment and patients with Long COVID. By capturing biometric data with our Health Lives Here app, we intend to go beyond one-way information flow to empower patients to more dynamically manage their health by rationalizing wearables data's effect on healthcare decision-making."

DataMEDS AI, Inc. is a B2i Digital Featured Company. B2i Digital's Featured Companies can be found at

Strategic Vision and Technology Platforms

DataMEDS aims to deliver a vertically aligned healthcare ecosystem that expands EinsteinRx's technological capabilities into medical, laboratory, and wearables fields through a proprietary blockchain. The Company plans to leverage unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient populations.

The Company intends to use Health Lives Here's patient-engagement infrastructure to consolidate electronic health data into its proprietary health-centered blockchain. This would enable patients to participate in data transaction revenue, reduce data friction for providers, and allow for tailored clinical trial offerings of both prescription drugs and proprietary nutraceutical products for patients seeking to achieve specific health goals. The model also places DataMEDS in areas where healthcare companies are increasingly focused on data interoperability, patient consent, and the use of real-world biometric information in care management and research workflows.

Market Context

According to SNS Insider, the U.S. blockchain in healthcare market was valued at $7.13 billion in 2023 and is projected to reach $595.31 billion by 2032, at a compounded annual growth rate (CAGR) of 63.5% (see Datavault AI's November 25, 2025 PharmacyChain license announcement).

According to Market Research Future, the global drone-enabled medical supplies pickup and delivery market was valued at $430 million in 2023 and is projected to reach $2.49 billion by 2032, at a CAGR of 21.20%.

According to Grand View Research, the GLP-1 receptor agonist market is expected to grow from $66 billion in 2025 to $185 billion in 2033, at a CAGR of 12.4%. Skeletal muscle loss is documented as a key side effect of GLP-1 therapies and a primary target indication for Tollo Health's proprietary supplement portfolio.

According to market research firm Nova1 Advisor, the U.S. telemedicine market size was $41.54 billion in 2025 and is projected to grow to $188.05 billion by 2035, representing an expected CAGR of 16.3%.

Capitalization and Outstanding Securities

As of the date of this press release, DataMEDS has 2,847,198 common shares outstanding. Certain stockholders holding approximately 1,533,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety (90) days from the day preceding the announcement.

There are currently 919,465 DataMEDS common shares deposited in the Depository Trust & Clearing Corporation (DTCC) available for trading. There are no debt or preferred equity securities of the Company eligible to convert into free trading common shares at this time. A total of 80,826 cash warrants are outstanding, each with a fixed exercise price of $35.00 per share, currently eligible to be exercised into free trading common shares.

Investors should refer to the Company's filings with the Securities and Exchange Commission for additional information regarding the Company's capitalization and outstanding securities.